Abercrombie & Fitch Co., Anacor Pharmaceuticals Inc and Civeo Corp (CVEO): Latest Insider Action

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) surged by more than 163% over the last year. Just last year the company received FDA approval for Kerydin, a topical toenail fungus medication. Anacor has Novartis AG (ADR) (NYSE:NVS)’s Sandoz unit backing the commercialization of its new treatment. The fourth quarter, which was the first fiscal quarter that included Kerydin sales, posted solid results. William Leland Edwards’ Palo Alto Investors upped its stake by a hefty 20% in Anacor Pharmaceuticals Inc (NASDAQ:ANAC) during the fourth quarter to 2.52 million shares valued at $81.33 million. Anacor is also among top 3 biotech picks of VHCP Management according to the latest 13F filing.

Civeo Corp (NYSE:CVEO) also received some insider trading action as Bradley J. Dodson, who is the company’s president, CEO and Director added some 91,600 shares at the price of $2.39 per share to his holding that now comprises of 553,275 shares.  Civeo Corp (NYSE:CVEO) was a wholly owned subsidiary of Oil States International until its spin-off last year. The company provides lodging services to oil firms and the recent decline in oil prices had a strong impact on the company’s financial results. Although the disappointing fourth quarter performance was expected, weak guidance provided by the company’s management has caused an even steeper slide in the stock price. 2015 revenues are expected to fall between $520 million and $560 million, and the EBIDTA range is between $130 million and $150 million. This compares badly with the $942.9 million revenues for 2014 and an EBIDTA of $339.8 million. David Einhorn‘s Greenlight Capital upped its stake by 74% in Civeo Corp (NYSE:CVEO) during the fourth quarter to 10.66 million shares valued at $43.8 million.

Disclosure: none